
Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to its next phase.
Clinilabs is to carry out Cybin’s Phase 1/2a clinical trial of CYB003 for treating Major Depressive Disorder (MDD). According to the company, this will be the first psilocybin analog to be evaluated in a Phase 1/2a trial for this particular disorder.